Suppr超能文献

在单剂量加强方案中使用水疱性口炎病毒和改良安卡拉痘苗病毒疫苗载体对猕猴体内的艾滋病病毒攻击实现高效控制。

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.

作者信息

Ramsburg Elizabeth, Rose Nina F, Marx Preston A, Mefford Megan, Nixon Douglas F, Moretto Walter J, Montefiori David, Earl Patricia, Moss Bernard, Rose John K

机构信息

Yale University School of Medicine, New Haven, Connecticut 06510, USA.

出版信息

J Virol. 2004 Apr;78(8):3930-40. doi: 10.1128/jvi.78.8.3930-3940.2004.

Abstract

Previous studies have shown that vaccination and boosting of rhesus macaques with attenuated vesicular stomatitis virus (VSV) vectors encoding Env and Gag proteins of simian immunodeficiency virus-human immunodeficiency virus (SHIV) hybrid viruses protect rhesus macaques from AIDS after challenge with the highly pathogenic SHIV 89.6P (23). In the present study, we compared the effectiveness of a single prime-boost protocol consisting of VSV vectors expressing SHIV Env, Gag, and Pol proteins to that of a protocol consisting of a VSV vector prime followed with a single boost with modified vaccinia virus Ankara (MVA) expressing the same SHIV proteins. After challenge with SHIV 89.6P, MVA-boosted animals controlled peak challenge viral loads to less than 2 x 10(6) copies/ml (a level significantly lower than that seen with VSV-boosted animals and lower than those reported for other vaccine studies employing the same challenge). MVA-boosted animals have shown excellent preservation of CD4(+) T cells, while two of four VSV-boosted animals have shown significant loss of CD4(+) T cells. The improved protection in MVA-boosted animals correlates with trends toward stronger prechallenge CD8(+)-T-cell responses to SHIV antigens and stronger postchallenge SHIV-neutralizing antibody production.

摘要

先前的研究表明,用编码猿猴免疫缺陷病毒-人类免疫缺陷病毒(SHIV)嵌合病毒Env和Gag蛋白的减毒水疱性口炎病毒(VSV)载体对恒河猴进行疫苗接种和加强免疫后,恒河猴在受到高致病性SHIV 89.6P攻击后可免受艾滋病感染(23)。在本研究中,我们比较了由表达SHIV Env、Gag和Pol蛋白的VSV载体组成的单次初免-加强免疫方案与由VSV载体初免后再用表达相同SHIV蛋白的改良痘苗病毒安卡拉(MVA)进行单次加强免疫的方案的有效性。在用SHIV 89.6P攻击后,接受MVA加强免疫的动物将攻击峰值病毒载量控制在低于2×10⁶拷贝/毫升(这一水平显著低于接受VSV加强免疫的动物,也低于其他采用相同攻击方式的疫苗研究报告的水平)。接受MVA加强免疫的动物显示出CD4⁺ T细胞的良好保存,而接受VSV加强免疫的四只动物中有两只显示出CD4⁺ T细胞的显著减少。接受MVA加强免疫的动物中增强的保护作用与攻击前对SHIV抗原的CD8⁺ T细胞反应更强以及攻击后SHIV中和抗体产生更强的趋势相关。

相似文献

引用本文的文献

4
Rhabdoviruses as vectors for vaccines and therapeutics.Rhabdoviruses 作为疫苗和治疗药物的载体。
Curr Opin Virol. 2020 Oct;44:169-182. doi: 10.1016/j.coviro.2020.09.003. Epub 2020 Oct 29.

本文引用的文献

4
New hope for an AIDS vaccine.艾滋病疫苗的新希望。
Nat Rev Immunol. 2002 Apr;2(4):239-50. doi: 10.1038/nri776.
5
Prospects for vaccine protection against HIV-1 infection and AIDS.预防HIV-1感染和艾滋病的疫苗保护前景。
Annu Rev Immunol. 2002;20:73-99. doi: 10.1146/annurev.immunol.20.081501.094854. Epub 2001 Oct 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验